High seed (HS) inoculation
is a novel approach that has established itself with the development of the single-use technology, and that aims towards producing the inoculum for mammalian cell-based antibody production processes in a continuous process via perfusion. The bioreactor is inoculated with an initial cell density of at least 1x106 cells mL-1 in order to reach the desired product concentration with a high product quality within a short time 35.